BELBUCA® Net Sales Increased by 134% versus Prior Year to All-time High of $18.7 Million
Symproic® Acquisition and Commercial Integration Successfully Completed
Company Raises Full-Year BELBUCA Net Sales Expectations to $83 - $88 Million
Confirms Full-Year Net Sales Expectations of $92 - $100 Million Including Symproic
Conference Call and Webcast scheduled for 4:30 PM ET Today
RALEIGH, N.C., May 06, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions, today reported strong financial results for the first quarter ended March 31, 2019, as well as the following operational and performance highlights:
Key Business Highlights:
- BELBUCA® (buprenorphine buccal film) CIII prescription growth experienced an all-time year-over-year record increase of 141% as well as a 16% increase versus prior quarter. The 65,230 prescriptions during the quarter also represents a record level for any three-month period.
- Total company revenue increased by 75% versus prior year to an all-time high of $19.8 million. Growth versus prior year was driven by strength of BELBUCA performance, partially offset by decline in Bunavail sales and timing of ex-US royalties.
- Achieved record quarter over quarter growth in unique prescribers during the first quarter, reaching an all-time high of nearly 6,000.
- Acquired rights to commercialize Symproic® (naldemedine) tablets 0.2 mg in the U.S. on April 4, with BDSI’s sales force fully trained and actively promoting Symproic as of May 2.
- Successfully raised $50 million of gross proceeds in an underwritten public equity offering in April.
“We had an outstanding start to the year as demonstrated by the continued strong growth momentum of BELBUCA and the recent acquisition of Symproic,” stated Herm Cukier, Chief Executive Officer of BDSI. “The ability to seamlessly acquire and integrate a new product into our portfolio while achieving record-setting sales performance is a testament to the strong operational capabilities of our organization and gives me utmost confidence in our ability to sustain growth momentum for rest of year.”
The company has increased its expectations for full-year 2019 BELBUCA net sales to $83 - $88 million from previous level of $80 - $85 million. The company also reiterated its total 2019 net sales expectations of $92 - $100 million, including Symproic 2019 net sales expectations of $7 - $9 million, and the expectation to have positive cash flow from operations by year end.
First Quarter 2019 Financial Results
Total Net Revenue. Total net revenue for the first quarter ended March 31, 2019, was $19.8 million, an increase of 10% compared to $18.0 million in the fourth quarter of 2018, and an increase of 75% compared to $11.3 million in the first quarter of 2018.
BELBUCA Net Sales. BELBUCA net sales in the first quarter ended March 31, 2019, was $18.7 million, an increase of 18% compared to $15.9 million in the fourth quarter 2018, and an increase of 134% compared to $8.0 million in the first quarter 2018.
Total Operating Expenses. Total operating expenses for the first quarter ended March 31, 2019, were $17.0 million, compared to $18.5 million in the fourth quarter of 2018, and $16.0 million in the first quarter of 2018.
Net Loss. Net loss for the first quarter ended March 31, 2019, was $3.8 million, or ($0.05) per share, compared to a loss of $7.0 million, or ($0.10) per share in the fourth quarter of 2018 and a loss of $10.7 million or ($0.18) per diluted share in the first quarter of 2018.
Conference Call & Webcast Details
BioDelivery Sciences will host a conference call and webcast today, May 6, 2019, at 4:30 p.m. ET to present first quarter 2019 results and to provide a business update. Dial-in details are as follows:
Conference Call Dial-In & Webcast Information:
| Date: | Monday, May 6, 2019 |
| Time: | 4:30 PM Eastern Time |
| Domestic: | 877-407-0789 |
| International: | 201-689-8562 |
| Passcode: | 13690336 |
| Webcast: | http://public.viavid.com/index.php?id=134355 |
ABOUT BIODELIVERY SCIENCES INTERNATIONAL, INC.
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs. BDSI's marketed products and those in development address serious and debilitating conditions such as chronic pain, breakthrough cancer pain, opioid dependence, and opioid induced constipation. For more information, please visit us at www.bdsi.com or follow us on Facebook.com/BioDeliverySI or Twitter BDSI @BioDeliverySI.
CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS
This press release and any statements of employees, representatives, and partners of BioDelivery Sciences International, Inc. (“BDSI”) related thereto contain, or may contain, among other things, certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the BDSI’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential” or similar expressions. These statements are based upon the current beliefs and expectations of the BDSI’s management and are subject to significant risks and uncertainties, including those detailed in the BDSI’s filings with the Securities and Exchange Commission. Actual results (including, without limitation, the continued growth in BELBUCA net revenues and total net revenues in 2019 and the implementation and success of our Symproic strategic plan) may differ materially from those set forth or implied in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the BDSI’s control) including those set forth in our 2018 annual report on Form 10-K filed with the US Securities and Exchange Commission and subsequent filings. BDSI undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.
© 2019 BioDelivery Sciences International, Inc. All rights reserved.
Contact:
Mary Coleman
Vice President Investor Relations and Corporate Communications
BioDelivery Sciences International, Inc.
1-919-582-9050
| BIODELIVERY SCIENCES INTERNATIONAL, INC. AND SUBSIDIARIES | ||||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||||
| (U.S. DOLLARS, IN THOUSANDS, EXCEPT SHARE AND PER SHARE AMOUNTS) | ||||||||
| (Unaudited) | ||||||||
| March 31, | December 31, | |||||||
| 2019 | 2018 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash | $ | 41,329 | $ | 43,822 | ||||
| Accounts receivable, net | 16,008 | 13,627 | ||||||
| Inventory, net | 7,259 | 5,406 | ||||||
| Prepaid expenses and other current assets | 2,970 | 3,188 | ||||||
| Total current assets | 67,566 | 66,043 | ||||||
| Property and equipment, net | 3,952 | 3,072 | ||||||
| Goodwill | 2,715 | 2,715 | ||||||
| BELBUCA license and distribution rights, net | 34,875 | 36,000 | ||||||
| Other intangible assets, net | 539 | 703 | ||||||
| Total assets | $ | 109,647 | $ | 108,533 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable and accrued liabilities | $ | 23,484 | $ | 21,539 | ||||
| Total current liabilities | 23,484 | 21,539 | ||||||
| Notes payable, net | 52,286 | 51,652 | ||||||
| Other long-term liabilities | 6,355 | 5,600 | ||||||
| Total liabilities | 82,125 | 78,791 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders' equity: | ||||||||
| Preferred Stock, 5,000,000 shares authorized; Series A Non-Voting Convertible Preferred Stock. $.001 par value, 2,093,155 shares outstanding at both March 31, 2019 and December 31, 2018, respectively; Series B Non-Voting Convertible Preferred Stock, $.001 par value, 2,400 and 3,100 shares outstanding at March 31, 2019 and December 31, 2018, respectively. | 2 | 2 | ||||||
| Common Stock, $.001 par value; 125,000,000 shares authorized at March 31, 2019, and December 31, 2018, respectively; 75,333,254 and 75,793,725 shares issued; 75,317,763 and 70,778,234 shares outstanding at March 31, 2019, and December 31, 2018, respectively. | 74 | 71 | ||||||
| Additional paid-in capital | 382,614 | 381,004 | ||||||
| Treasury stock, at cost, 15,491 shares | (47 | ) | (47 | ) | ||||
| Accumulated deficit | (355,121 | ) | (351,288 | ) | ||||
| Total stockholders' equity | 27,522 | 29,742 | ||||||
| Total liabilities and stockholders' equity | $ | 109,647 | $ | 108,533 | ||||
| BIODELIVERY SCIENCES INTERNATIONAL, INC. AND SUBSIDIARIES | ||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||
| (U.S. DOLLARS, IN THOUSANDS, EXCEPT SHARE AND PER SHARE AMOUNTS) | ||||||||
| Three Months Ending March 31, | ||||||||
| 2019 | 2018 | |||||||
| Revenues: | ||||||||
| Product sales | 19,759 | 9,838 | ||||||
| Product royalty revenues | 2 | 440 | ||||||
| Contract revenue | 8 | 1,003 | ||||||
| Total Revenues | 19,769 | 11,281 | ||||||
| Cost of sales | 4,052 | 3,415 | ||||||
| Expenses: | ||||||||
| Research and development: | - | 2,484 | ||||||
| Selling, general and administrative | 16,989 | 13,505 | ||||||
| Total expenses | 16,989 | 15,989 | ||||||
| Loss from operations | (1,272 | ) | (8,123 | ) | ||||
| Interest expense, net | (2,561 | ) | (2,505 | ) | ||||
| Other expense, net | - | (7 | ) | |||||
| Loss before income taxes | $ | (3,833 | ) | $ | (10,635 | ) | ||
| Income tax expense | - | (74 | ) | |||||
| Net loss attributable to common stockholders | $ | (3,833 | ) | $ | (10,709 | ) | ||
| Basic and diluted: | ||||||||
| Weighted average common stock shares outstanding | 71,344,831 | 58,062,997 | ||||||
| Basic and diluted loss per share | $ | (0.05 | ) | $ | (0.18 | ) | ||
| BIODELIVERY SCIENCES INTERNATIONAL, INC. AND SUBSIDIARIES | ||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||||||
| (U.S. DOLLARS, IN THOUSANDS) | ||||||||||
| Three Months Ending March 31, | ||||||||||
| 2019 | 2018 | |||||||||
| Operating activities: | ||||||||||
| Net loss | $ | (3,833 | ) | $ | (10,709 | ) | ||||
| Adjustments to reconcile net loss to net cash flows from operating activities | ||||||||||
| Depreciation | 85 | 230 | ||||||||
| Accretion of debt discount and loan costs | 634 | 625 | ||||||||
| Amortization of Intangible Assets | 1,289 | 1,289 | ||||||||
| Provision (benefit) for inventory obsolescence | 149 | (66 | ) | |||||||
| Stock based compensation expense | 1,141 | 2,921 | ||||||||
| Changes in assets and liabilities, net of effect of acquisition: | ||||||||||
| Accounts receivable | (2,381 | ) | 864 | |||||||
| Inventories | (2,002 | ) | 716 | |||||||
| Prepaid expenses and other assets | 218 | 782 | ||||||||
| Accounts payable and accrued expenses | 1,814 | (3,413 | ) | |||||||
| Deferred revenue | - | - | ||||||||
| Net cash flows from operating activities | (2,886 | ) | (6,761 | ) | ||||||
| Investing activities: | ||||||||||
| BELBUCA Acquisitions | - | (1,951 | ) | |||||||
| Purchase of equipment | - | (73 | ) | |||||||
| Disposal of property and equipment | (79 | ) | - | |||||||
| Net cash flows from investing activities | (79 | ) | (2,024 | ) | ||||||
| Financing activities: | ||||||||||
| Proceeds from exercise of stock options | 472 | 130 | ||||||||
| Payment of deferred financing fees | - | (450 | ) | |||||||
| Net cash flows from financing activities | 472 | (320 | ) | |||||||
| Net change in cash and cash equivalents | (2,493 | ) | (9,105 | ) | ||||||
| Cash and cash equivalents at beginning of year | 43,822 | 21,195 | ||||||||
| Cash and cash equivalents at end of year | $ | 41,329 | $ | 12,090 | ||||||
| Cash paid for interest | $ | 1,931 | $ | 1,880 | ||||||